AtomVie inaugurates cutting‑edge radiopharmaceutical manufacturing plant in Hamilton, boosting North American CDMO capacity
Executive summary: AtomVie opened a new state‑of‑the‑art radiopharmaceutical manufacturing facility in Hamilton, Ontario on September 4, 2026. The facility expands AtomVie’s CDMO capabilities for radiopharmaceuticals, strengthening the regional supply chain for nuclear medicine and supporting increased demand for diagnostic and therapeutic agents.
Who is involved: AtomVie Global Radiopharma (CDMO), Ontario life‑science stakeholders, and the broader radiopharmaceutical industry.
Likely next: The plant is expected to commence commercial production shortly, with AtomVie likely to pursue additional radiopharmacy contracts and consider further site expansion.
AtomVie has opened a new radiopharmaceutical manufacturing facility in Hamilton, Ontario, describing the plant as cutting‑edge and aimed at strengthening its contract development and manufacturing organization (CDMO) services. The plant is intended to handle both diagnostic and therapeutic radiopharmaceuticals, adding to the company’s production capabilities in North America. The inauguration comes at a time when demand for radiopharmaceuticals is rising due to expanding use in imaging and targeted therapies, while the region’s CDMO capacity has been seen as a potential bottleneck. By providing additional manufacturing space and technical infrastructure, AtomVie can better support clients needing reliable supply for clinical trials and commercial distribution. In the near term, the facility is likely to take on new contracts, contribute to local employment, and reinforce Hamilton’s role as a hub for nuclear medicine production, without requiring any further speculation about specific client names, contract values, or timelines beyond what the announcement states.
Timeline
- — AtomVie celebra la inauguración de sus nuevas instalaciones de fabricación de última generación en Hamilton (PR Newswire)
Analysis — what this means
Sectors affected
- Radiopharmaceutical manufacturing
- Nuclear medicine
- Contract development and manufacturing organization (CDMO) services
Regulatory implications
- Must obtain licensing from the Canadian Nuclear Safety Commission (CNSC) for radiopharmaceutical production
- Compliance with FDA current Good Manufacturing Practice (cGMP) standards for radiopharmaceuticals
- Adherence to Environmental Protection Agency (EPA) regulations for radioactive waste management
Key entities
Sources
Open the full interactive case file on Beyond →